OS Therapies' (OSTX) "Buy" Rating Reiterated at D. Boral Capital

Key Points

• OS Therapies (NYSE:OSTX) has had its "buy" rating reaffirmed by D. Boral Capital, which also set a price target of $20.00 for the stock.
• During recent trading, the stock price decreased to $2.1290 with a market cap of $67.33 million and a PE ratio of -2.48.
• Major institutional investments include Bridgeway Capital Management acquiring a position worth approximately $47,000 and CM Management LLC increasing its stake by 172.6%.

OS Therapies (NYSE:OSTX - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $20.00 price target on the stock.

OS Therapies Stock Performance

NYSE:OSTX traded down $0.20 during mid-day trading on Wednesday, hitting $2.28. The stock had a trading volume of 1,094,815 shares, compared to its average volume of 739,769. OS Therapies has a twelve month low of $1.12 and a twelve month high of $7.00. The stock has a market cap of $72.71 million and a price-to-earnings ratio of -2.88. The company's 50 day simple moving average is $1.83 and its 200 day simple moving average is $1.73.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of OSTX. Bridgeway Capital Management LLC acquired a new position in OS Therapies in the 2nd quarter valued at about $47,000. XTX Topco Ltd acquired a new position in OS Therapies in the 2nd quarter valued at about $63,000. Finally, CM Management LLC grew its stake in OS Therapies by 172.6% in the 1st quarter. CM Management LLC now owns 300,000 shares of the company's stock valued at $462,000 after buying an additional 189,956 shares during the last quarter.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.